Premium
Inflammation‐mediated obesity and insulin resistance as targets for nutraceuticals
Author(s) -
Kim MyungSunny,
Lee Myeong Soo,
Kown Dae Young
Publication year - 2011
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2011.06098.x
Subject(s) - insulin resistance , inflammation , obesity , nutraceutical , medicine , diabetes mellitus , endocrinology , pathology
Obesity‐induced inflammation plays an important role in the development of insulin resistance, type 2 diabetes (T2D), and metabolic dysfunctions. Chronic activation of proinflammatory pathways within insulin target cells can lead to obesity‐related insulin resistance. The inflammatory mediators consist of immune cells, cytokines, adipokines, and inflammatory signaling molecules. Targeting obesity‐associated inflammation has been shown to protect experimental animals and human subjects from obesity‐induced insulin resistance. Modulation of the inflammatory responses associated with obesity may help prevent or improve obesity‐induced metabolic dysfunctions. In this review, we introduce the beneficial effects of nutraceuticals for targeting inflammation in the treatment of obesity‐induced insulin resistance and metabolic dysfunctions.